Follicular Lymphoma

Andrew MorenoTransplantation & Cellular Therapy | July 18, 2024
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Patrick DalyFollicular Lymphoma | October 4, 2024
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Patrick DalyIndolent B-Cell Lymphoma | December 22, 2023
Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL.
Advertisement
Patrick DalyIndolent B-Cell Lymphoma | December 22, 2023
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy during their lifetime.
Patrick DalyFollicular Lymphoma | October 18, 2023
The Committee for Medicinal Products for Human Use of the European Medicines Agency supported approving zanubrutinib for FL.
Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Advertisement
Kerri FitzgeraldAggressive B-Cell Lymphoma | November 14, 2022
The European Commission has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of ...
Leah SherwoodAggressive B-Cell Lymphoma | November 14, 2022
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
Leah LawrenceIndolent B-Cell Lymphoma | November 22, 2022
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022
The CAR T-cell therapy was approved for adult follicular lymphoma patients who have received two or more lines of systemic ...
Sabrina AhleIndolent B-Cell Lymphoma | November 14, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Rob DillardChronic Lymphocytic Leukemia | February 2, 2023
Research indicates that Hispanic patients with DLBCL have better survival than non-Hispanic White.
Advertisement
Advertisement